Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions

Shigeo Koido; Sadamu Homma; Masato Okamoto; Yoshihisa Namiki; Kazuki Takakura; Kan Uchiyama; Mikio Kajihara; Seiji Arihiro; Hiroo Imazu; Hiroshi Arakawa; Shin Kan; Hideo Komita; Yuko Kamata; Masaki Ito; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri

doi:10.4161/onci.25994

Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions

Shigeo Koido, Sadamu Homma, Masato Okamoto, Yoshihisa Namiki, Kazuki Takakura, Kan Uchiyama, Mikio Kajihara, Seiji Arihiro, Hiroo Imazu, Hiroshi Arakawa, Shin Kan, Hideo Komita, Yuko Kamata, Masaki Ito, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

The rationale for fusing dendritic cells (DCs) with whole tumor cells to generate anticancer vaccines resides in the fact that the former operate as potent antigen-presenting cells, whereas the latter express a constellation of tumorassociated antigens (TAA s). Although the administration of DC/malignant cell fusions to cancer patients is safe and this immunotherapeutic intervention triggers efficient tumorspecific T-cell responses in vitro, a limited number of objective clinical responses to DC/cancer cell fusions has been reported thus far. This review discusses novel approaches to improve the immunogenicity of DC/malignant cell fusions as anticancer vaccines.

Original language	English
Article number	e25994
Journal	OncoImmunology
Volume	2
Issue number	9
DOIs	https://doi.org/10.4161/onci.25994
State	Published - 2013
Externally published	Yes

Keywords

Cytotoxic T lymphocyte
Dendritic cell
Fusion
Immunogenicity
Whole tumor cell

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4161/onci.25994

Cite this

Koido, S., Homma, S., Okamoto, M., Namiki, Y., Takakura, K., Uchiyama, K., Kajihara, M., Arihiro, S., Imazu, H., Arakawa, H., Kan, S., Komita, H., Kamata, Y., Ito, M., Ohkusa, T., Gong, J., & Tajiri, H. (2013). Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions. OncoImmunology, 2(9), Article e25994. https://doi.org/10.4161/onci.25994

@article{294dc510c1054054b697048275ca5a63,

title = "Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions",

abstract = "The rationale for fusing dendritic cells (DCs) with whole tumor cells to generate anticancer vaccines resides in the fact that the former operate as potent antigen-presenting cells, whereas the latter express a constellation of tumorassociated antigens (TAA s). Although the administration of DC/malignant cell fusions to cancer patients is safe and this immunotherapeutic intervention triggers efficient tumorspecific T-cell responses in vitro, a limited number of objective clinical responses to DC/cancer cell fusions has been reported thus far. This review discusses novel approaches to improve the immunogenicity of DC/malignant cell fusions as anticancer vaccines.",

keywords = "Cytotoxic T lymphocyte, Dendritic cell, Fusion, Immunogenicity, Whole tumor cell",

author = "Shigeo Koido and Sadamu Homma and Masato Okamoto and Yoshihisa Namiki and Kazuki Takakura and Kan Uchiyama and Mikio Kajihara and Seiji Arihiro and Hiroo Imazu and Hiroshi Arakawa and Shin Kan and Hideo Komita and Yuko Kamata and Masaki Ito and Toshifumi Ohkusa and Jianlin Gong and Hisao Tajiri",

year = "2013",

doi = "10.4161/onci.25994",

language = "英語",

volume = "2",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "9",

}

Koido, S, Homma, S, Okamoto, M, Namiki, Y, Takakura, K, Uchiyama, K, Kajihara, M, Arihiro, S, Imazu, H, Arakawa, H, Kan, S, Komita, H, Kamata, Y, Ito, M, Ohkusa, T, Gong, J & Tajiri, H 2013, 'Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions', OncoImmunology, vol. 2, no. 9, e25994. https://doi.org/10.4161/onci.25994

TY - JOUR

T1 - Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions

AU - Koido, Shigeo

AU - Homma, Sadamu

AU - Okamoto, Masato

AU - Namiki, Yoshihisa

AU - Takakura, Kazuki

AU - Uchiyama, Kan

AU - Kajihara, Mikio

AU - Arihiro, Seiji

AU - Imazu, Hiroo

AU - Arakawa, Hiroshi

AU - Kan, Shin

AU - Komita, Hideo

AU - Kamata, Yuko

AU - Ito, Masaki

AU - Ohkusa, Toshifumi

AU - Gong, Jianlin

AU - Tajiri, Hisao

PY - 2013

Y1 - 2013

N2 - The rationale for fusing dendritic cells (DCs) with whole tumor cells to generate anticancer vaccines resides in the fact that the former operate as potent antigen-presenting cells, whereas the latter express a constellation of tumorassociated antigens (TAA s). Although the administration of DC/malignant cell fusions to cancer patients is safe and this immunotherapeutic intervention triggers efficient tumorspecific T-cell responses in vitro, a limited number of objective clinical responses to DC/cancer cell fusions has been reported thus far. This review discusses novel approaches to improve the immunogenicity of DC/malignant cell fusions as anticancer vaccines.

AB - The rationale for fusing dendritic cells (DCs) with whole tumor cells to generate anticancer vaccines resides in the fact that the former operate as potent antigen-presenting cells, whereas the latter express a constellation of tumorassociated antigens (TAA s). Although the administration of DC/malignant cell fusions to cancer patients is safe and this immunotherapeutic intervention triggers efficient tumorspecific T-cell responses in vitro, a limited number of objective clinical responses to DC/cancer cell fusions has been reported thus far. This review discusses novel approaches to improve the immunogenicity of DC/malignant cell fusions as anticancer vaccines.

KW - Cytotoxic T lymphocyte

KW - Dendritic cell

KW - Fusion

KW - Immunogenicity

KW - Whole tumor cell

UR - http://www.scopus.com/inward/record.url?scp=84890278140&partnerID=8YFLogxK

U2 - 10.4161/onci.25994

DO - 10.4161/onci.25994

M3 - 総説

AN - SCOPUS:84890278140

SN - 2162-4011

VL - 2

JO - OncoImmunology

JF - OncoImmunology

IS - 9

M1 - e25994

ER -

Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this